$44.9 Million is the total value of Asymmetry Capital Management, L.P.'s 22 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DVA | New | DAVITA HEALTHCARE PARTNERS I | $4,071,000 | – | 56,290 | +100.0% | 9.07% | – |
| EW | New | EDWARDS LIFESCIENCES CORP | $3,920,000 | – | 27,574 | +100.0% | 8.73% | – |
| DGX | New | QUEST DIAGNOSTICS INC | $3,720,000 | – | 60,520 | +100.0% | 8.29% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $3,259,000 | – | 232,957 | +100.0% | 7.26% | – |
| NVRO | New | NEVRO CORP | $2,860,000 | – | 61,660 | +100.0% | 6.37% | – |
| CNC | New | CENTENE CORP | $2,754,000 | – | 50,784 | +100.0% | 6.13% | – |
| TEVA | New | TEVA PHARMACEUTICAL-SP ADRadr | $2,715,000 | – | 48,085 | +100.0% | 6.05% | – |
| SYK | New | STRYKER CORP | $2,614,000 | – | 27,781 | +100.0% | 5.82% | – |
| MDXG | New | MIMEDX GROUP INC | $2,218,000 | – | 229,839 | +100.0% | 4.94% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $1,970,000 | – | 49,500 | +100.0% | 4.39% | – |
| ENDP | New | ENDO INTERNATIONAL PLC | $1,843,000 | – | 26,600 | +100.0% | 4.10% | – |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $1,770,000 | – | 29,900 | +100.0% | 3.94% | – |
| AERI | New | AERIE PHARMACEUTICALS INC | $1,523,000 | – | 85,834 | +100.0% | 3.39% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $1,513,000 | – | 16,458 | +100.0% | 3.37% | – |
| SGNT | New | SAGENT PHARMACEUTICALS INC | $1,414,000 | – | 92,213 | +100.0% | 3.15% | – |
| IPXL | New | IMPAX LABORATORIES INC | $1,348,000 | – | 38,279 | +100.0% | 3.00% | – |
| VNDA | New | VANDA PHARMACEUTICALS INC | $1,339,000 | – | 118,707 | +100.0% | 2.98% | – |
| XNPT | New | XENOPORT INC | $1,278,000 | – | 368,395 | +100.0% | 2.85% | – |
| New | ANACOR PHARMACEUTICALS INC | $1,100,000 | – | 9,349 | +100.0% | 2.45% | – | |
| SGYPQ | New | SYNERGY PHARMACEUTICALS INC | $1,077,000 | – | 203,155 | +100.0% | 2.40% | – |
| PEN | New | PENUMBRA INC | $400,000 | – | 9,980 | +100.0% | 0.89% | – |
| EPRSQ | New | EPIRUS BIOPHARMACEUTICALS IN | $189,000 | – | 42,787 | +100.0% | 0.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.